Publications

Frequency and antimicrobial susceptibility of bacterial pathogens isolated from bloodstream infections in haematology-oncology patients: results from the Latin America SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Andrade SS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Frequency of occurrence and antimicrobial susceptibility profile of pathogens causing bloodstream infections in paediatric patients from Latin America: report of SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Gales AC, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial spectrum and activity of NVP PDF-713 (PDF7), a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Potential utility of a peptide deformylase inhibitor, NVP PDF-713 (PDF7) against oxazolidinone-resistant or streptogramin-resistant Gram-positive isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Determination of quality control guidelines for MIC dilution and disk diffusion methods when testing NVP-PDF713, a novel peptide deformylase inhibitor, Lead author: Fritsche TR, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Determination of dry-form commercial reagent reproducibility and MIC validations for NVP-PDF713, a novel peptide deformylase inhibitor, Lead author: Moet G, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Once-weekly dalbavancin in catheter-related bloodstream infections: microbiological findings, Lead author: Goldstein BP, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Evaluations of Dalbavancin (DAL) activity and spectrum tested against European isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

In vitro activity of the glycylcycline tigecycline tested against a worldwide collection of 10,127 contemporary Staphylococci, Streptococci and Enterococci, Lead author: Fritsche TR, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial activity of tigecycline (GAR-936) tested against enterobacteriaceae, and selected non-fermentative Gram-negative bacilli, a worldwide sample, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Activity of tigecycline tested against clinical isolates of Haemophilus influenzae, Moraxella catarrhalis and Neisseria menigitidis, a worldwide perspective, Lead author: Sader HS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Potency and Spectrum Re-Evaluation of Cefdinir Tested Against Pathogens Causing Skin and Soft Tissue Infections (SSTI):A Sample of North American Isolates, Lead author: Jones RN, presented at 11th annual International Congress on Infectious Diseases (ICID), March 4 – 7, 2004, Cancun, Mexico

Contemporary Cefdinir Activity against North American Isolates from Community-acquired Urinary Tract Infections (CA-UTI), Lead author: Sader HS, presented at 11th annual International Congress on Infectious Diseases (ICID), March 4 – 7, 2004, Cancun, Mexico

Increasing Resistance (R) of Pseudomonas aeruginosa (PSA), Staphylococcus aureus (SA), Klebsiella spp. (KSP), and Acinetobacter spp. (ASP) in Patients with Pneumonia in Latin America (LA): Report from the SENTRY Antimicrobial Surveillance Program, 2002, Lead author: Fritsche TR, presented at 11th annual International Congress on Infectious Diseases (ICID), March 4 – 7, 2004, Cancun, Mexico

Antimicrobial Susceptibility of Burkholderia cepacia in Latin America: Report from the SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Sibert S, presented at 11th annual International Congress on Infectious Diseases (ICID), March 4 – 7, 2004, Cancun, Mexico

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. by Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS published in J. Antimicrob. Chemother. 2004; 54 (1): 144-154

Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). by Streit JM, Jones RN, Sader HS and Fritsche TR published in Int. J. Antimicrob. Agents 2004; 24 (2): 111-118

Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: Spectrum of antimicrobial activity and measurements of bactericidal activity. by Sader HS, Fedler KA, Rennie RP, Stevens S and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (8): 3112-3118

Does the use of antibiotics in food animals pose a risk to human health? A reply to critics. by Phillips I, Casewell M, Cox T, de Groot B, Friis C, Jones R, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 54 (1): 276-278

Development of a standardized susceptibility test for Campylobacter with quality control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. by McDermott P, Bodeis S, Aarestrup F, Brown S, Traczewski M, Fedorka-Cray P, Wallace M, Critchley I, Thornsberry C, Graff S, Flamm R, Beyer J, Shortridge D, Piddock L, Ricci V, Johnson M, Jones R, Reller B, Mirrett S, Aldrobi J, Rennie R, Brosnikoff C published in Microbial. Drug Resist. 2004; 10 (2): 124-131

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. by Fritsche TR, Kirby JT and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 49 (3): 201-209

Determination of epidemic clonality among multi-drug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). by Jones RN, Deshpande L, Fritsche TR, Sader HS published in Diagn. Microbiol. Infect. Dis. 2004; 49 (3): 211-216

Quality control guidelines for BAL9141 (RO 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used. by Anderegg TR, Jones RN and Sader HS published in J. Clin. Microbiol. 2004; 42 (7): 3356-3358

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: Results from five years of the SENTRY Antimicrobial Surveillance Program. by Castanheira M, Gales AC, Mendes RE, Jones RN and Sader HS published in Clin. Microbiol. Infect. 2004; 10 (7): 645-651

Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). by Jones RN, Sader HS and Fristche TR published in Diagn. Microbiol. Infect. Dis. 2004; 49 (2):147-149

Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY Program, 1999 to 2001. by Christiansen KJ, Bell JM, Turnidge JD, Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (6): 2049-2055

Emergence of the extended-spectrum beta-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: Report from the SENTRY Antimicrobial Surveillance Program. by Castanheira M, Mendes RE, Walsh TR, Gales AC and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (6): 2344-2345

Antibiotic use in animals. by Phillips I, Casewell M, Cox T, DeGroot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (5): 885

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. by Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM, Piedmonte M and Jones RN published in Clin. Infect. Dis. 2004; 38 (11): 1513-1520

Antimicrobial spectrum and activity of NVP PDF-713, A novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. by Jones RN, Fritsche TR and Sader HS published in Diagn. Microbiol Infect. Dis. 2004; 49 (1): 63-65

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. by Jones RN, Moet GJ, Sader HS and Fritsche TR published in J. Antimicrob. Chemother. 2004; 53 (5): 804-807

Daptomycin activity and spectrum: A worldwide sample of 6,737 clinical Gram-positive organisms. by Streit JM, Jones RN, Sader HS published in J. Antimicrob. Chemother. 2004; 53 (4): 669-674

Letters to the editor: First isolation of bla_VIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. by Mendes RE, Castanheira M, Garcia P, Guzman M, Toleman MA, Walsh TR and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (4): 1433-1434

A pragmatic approach to identify extended-spectrum beta-lactamse-producing Klebsiella pneumoniae in Taiwan: in vitro activity of newer and established antimicrobial agents. by Yu, W-L, Chuang, Y-C, Jones, RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (4): 277-282

Pseudomonas aeruginosa strains harbouring an unusual bla_VIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). by Patzer J, Toleman MA, Deshpande LM, Kaminska W, Dzierzanowska D, Bennett PM, Jones RN and Walsh TR published in J. Antimicrob. Chemother. 2004; 53 (3): 451-456

Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI226), a novel antimicrobial peptide. by Anderegg T.R., Fritsche TR and Jones RN published in J. Clin. Microbiol. 2004; 42 (3): 1386-1387

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. by Streit JM, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 137-143

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 101-105

Antibiotic resistance in hospitalized patients: MYSTIC Program (1999-2002). by Rhomberg PR, Fritsche TR, Sader HS, Jones RN published in Antibiot. Clin. 2003; 7 (Suppl 2): 2-7

Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: Report from the Garenoxacin International Bridging Study. by Jones RN, Gordon KA, Biedenbach DJ published in J. Antimicrob. Chemother. 2004; 53 (2): 258-265

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). by Mutnick AH, Rhomberg PR, Sader HS, Jones RN published in J. Antimicrob. Chemother. 2004; 53 (2): 290-296

Disk diffusion quality control guidelines for NVP PDF-713: A novel peptide deformylase inhibitor. by Anderegg TR, Jones RN, The Quality Control Working Group published in Diagn. Microbiol. Infect. Dis. 2004; 48 (1): 55-57

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. by Jones RN, Streit JM and Fritsche TR published in Int. J. Antimicrob. Agents. 2004; 23 (2): 197-199

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States Medical Centres. by Rhomberg PR, Jones RN, Sader HS and MYSTIC Programme Study Group published in Int. J. Antimicrob. Agents 2004; 23 (1): 52-59

Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. by Anderegg TR and Jones RN published in Int. J. Antimicrob. Agents 2004; 23 (1): 6-10

Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). by Kirby JT, Sader HS, Walsh TR and Jones RN published in J. Clin. Microbiol. 2004; 42 (1): 445-448

Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. by Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (1): 28-52

Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan. by Yu W-L, Wu L-T, Pfaller MA, Winokur PL and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (1): 362-363

bla_VIM-7, an evolutionary distinct metallo-beta-lactamsae gene in a Pseudomonas aeruginosa isolate from the United States. by Toleman MA, Rolston K, Jones RN and Walsh TR published in Antimicrob. Agents Chemother. 2004; 48 (1): 329-332

Are Enterococcus faecalis strains with vat(E) in poultry a reservoir for human streptogramin resistance? vat(E) occurrence in human enterococcal bloodstream infections in North America (SENTRY Antimicrobial Surveillance Program, 2002). by Jones RN, Deshpande LM published in Antimicrob. Agents Chemother. 2004; 48 (1): 360-361